Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Down – Time to Sell?

Fresenius SE & Co. (OTCMKTS:FSNUY)’s share price gapped down before the market opened on Thursday. The stock had previously closed at $12.19, but opened at $11.63. Fresenius SE & Co. shares last traded at $11.6825, with a volume of 18,360 shares.

Analyst Upgrades and Downgrades

FSNUY has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating. According to MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a market capitalization of $26.99 billion, a price-to-earnings ratio of 15.16 and a beta of 0.60. The business’s 50 day simple moving average is $13.12 and its 200-day simple moving average is $12.37.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The business had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. Research analysts anticipate that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.